MILONTIN Drug Patent Profile
✉ Email this page to a colleague
When do Milontin patents expire, and when can generic versions of Milontin launch?
Milontin is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in MILONTIN is phensuximide. Additional details are available on the phensuximide profile page.
Summary for MILONTIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 56 |
Patent Applications: | 2,187 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MILONTIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MILONTIN
US Patents and Regulatory Information for MILONTIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Parke Davis | MILONTIN | phensuximide | CAPSULE;ORAL | 008855-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |